

NAMPT Inhibitor Market by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

<https://marketpublishers.com/r/N14B3DBF9152EN.html>

Date: September 2022

Pages: 141

Price: US\$ 4,799.00 (Single User License)

ID: N14B3DBF9152EN

Abstracts

The NAMPT inhibitor market is projected to experience a substantial growth with a compound annual growth rate (CAGR) of 15% during the forecast period, driven by the escalating burden of cancer patients. A study published in the American Cancer Society Journal has estimated that by 2040, the number of cancer cases will surpass 28 million, reflecting a cumulative growth of nearly 47% since 2020. This persistent rise in cancer patient numbers places a significant strain on both financial and healthcare resources. Notably, the annual expenditure related to cancer care in the US alone exceeds USD 200 billion.

As the majority of current cancer treatment options, particularly for late-stage cancers, are deemed inadequate, there is a pressing demand for highly effective therapeutics. Over time, numerous research studies have revealed that NAMPT (Nicotinamide Phosphoribosyl Transferase) can disrupt the metabolism of NAD⁺, which serves as the fuel for tumor cells. This concept has spurred extensive research into the development

of novel and efficacious drug candidates, namely NAMPT inhibitors. NAMPT inhibitors are under evaluation for a wide range of indications, with a primary focus on oncological disorders. Encouraging research outcomes have garnered significant attention from private and public investors, resulting in investments exceeding USD 650 million since 2018. Fueled by increasing R&D activities, promising clinical data, and substantial financial support, the NAMPT inhibitor market is poised for remarkable growth in the forecast period.

Key Market Segments

Type of Molecule

Small Molecules

Biologics

Type of Therapeutic Area

Oncological Disorders

Respiratory Disorders

Type of Indication

Non-Hodgkin Lymphoma

Hodgkin Lymphoma

Acute Respiratory Distress Syndrome

Acute Myeloid Leukemia

Route of Administration

Oral

Intravenous

Line of Treatment

First Line

Second Line

Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

The report studies the NAMPT inhibitor market by type of molecule, therapeutic area, indication, route of administration, line of treatment and key geographical regions

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to major regions.

A comprehensive overview of the current market landscape for NAMPT targeting drug candidates currently under research in pre-clinical and clinical

studies.

A detailed analysis of recent partnerships and collaborations among stakeholders in the NAMPT inhibitor domain since 2022.

An insightful analysis of recent funding instances reported by players in the NAMPT inhibitor market, including information on the year of funding, the amount received, and the type of funding.

An in-depth analysis of various grants received by players in this field since 2022, based on the year of the award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.

An insightful company competitiveness analysis of NAMPT inhibitor therapy developers based on various relevant parameters, such as portfolio strength, partnership strength and funding strength.

Comprehensive profiles of prominent players engaged in the development of NAMPT inhibitors, providing an overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments, and an informed future outlook.

A detailed analysis of several peer-reviewed scientific articles related to research on NAMPT inhibitors over the last 12 years, based on parameters such as the year of publication, type of publication, and popular keywords.

An analysis of global events attended by industry players, considering various parameters such as the year of the event, event platform, type of event, leading presenters (in terms of the number of participations), and leading players (in terms of the number of participations).

An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter. This analysis considers parameters like the year of the tweet, top users, and emerging focus areas.

An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, considering various relevant parameters, such as the phase of discontinuation, target indication, route of administration, and

type of molecule.

A proprietary analysis of various competitive strategies that can be implemented by drug developers in the NAMPT inhibitor market to expedite the FDA approval process for their proprietary products. This analysis includes information on various parameters, such as clinical evidence, awards/grants, research findings, partnerships, other financial support received, and more.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the container closure integrity testing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.

Key Market Companies

Antengene Therapeutics

Aqualung Therapeutics

Karyopharm Therapeutics

OncoTartis

Onxeo

Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION

- 2.1. Overview of NAMPT Inhibitors
- 2.2. Key Historical Events Related to NAMPT Inhibitors
- 2.3. NAMPT Inhibitors: Recent Activity
- 2.4. NAMPT Inhibitors: Mechanism of Action
- 2.5. NAMPT Inhibitors: Key Target Indications

3. MARKET LANDSCAPE

- 3.1. NAMPT Inhibitors: Pipeline Review
 - 3.1.1. Analysis by Phase of Development
 - 3.1.2. Analysis by Type of Molecule
 - 3.1.3. Analysis by Phase of Development and Type of Molecule
 - 3.1.4. Analysis by Type of Therapy
 - 3.1.5. Analysis by Line of Treatment
 - 3.1.5. Analysis by Route of Administration
- 3.2. NAMPT Inhibitors: Developer Landscape
 - 3.2.1. Analysis by Type of Player
 - 3.2.2. Analysis by Year of Establishment
 - 3.2.3. Analysis by Location of Headquarters
 - 3.2.4. Analysis by Location of Headquarters and Stage of Development
 - 3.2.5. Analysis by Location of Headquarters and Phase of Development
 - 3.2.6. Analysis by Location of Headquarters and Type of Molecule

4. PARTNERSHIPS AND COLLABORATIONS

- 4.1. NAMPT Inhibitors: Partnerships and Collaborations
 - 4.1.1. Analysis by Year of Partnership
 - 4.1.2. Analysis by Type of Partnership
 - 4.1.3. Analysis by Year and Type of Partnership
 - 4.1.4. Analysis by Type of Agreement
 - 4.1.5. Analysis by Intercontinental and Intracontinental Deals
 - 4.1.6. Active Players: Analysis by Number of Partnerships

5. FUNDING AND INVESTMENTS

5.1. NAMPT Inhibitors: Funding and Investments

- 5.1.1. Analysis of Instances by Year
- 5.1.2. Analysis of Amount Raised by Year
- 5.1.3. Analysis of Number of Instances Year and Type of Funding
- 5.1.4. Analysis of Amount Raised by Year and Type of Funding
- 5.1.5. Analysis of Number of Instances by Type of Funding
- 5.1.6. Analysis of Amount Raised by Type of Funding
- 5.1.7. Most Active Investors: Analysis by Number of Funding Instances
- 5.1.8. Active Players: Analysis by Number of Instances
- 5.1.9. Active Players: Analysis by Amount Raised
- 5.1.10. Analysis of Instances by Geography
- 5.1.11. Analysis of Total Amount Raised by Geography
- 5.1.12. Analysis of Total Amount Raised by Year of Establishment
- 5.1.13. Concluding Remarks

6. GRANTS ANALYSIS

6.1. Scope and Methodology

6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health

- 6.2.1. Analysis of Instances by Year
- 6.2.2. Analysis of Amount Awarded by Year
- 6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
- 6.2.4. Prominent Program Officers: Analysis by Number of Grants
- 6.2.5. Analysis by Type of Recipient Organization
- 6.2.6. Analysis of Instances by Year
- 6.2.7. Analysis by Purpose of Grant Award
- 6.2.8. Analysis by Funding Institute
- 6.2.9. Analysis by Support Period
- 6.2.10. Analysis by Funding Institute and Support Period
- 6.2.11. Analysis by Activity Code
- 6.2.12. Analysis by Type of Application
- 6.2.13. Word Cloud of NIH Spending Categories

7. COMPANY COMPETITIVENESS

7.1. Key Assumptions and Parameters

7.2. Methodology

- 7.3. Benchmarking of Portfolio Strength
- 7.4. Benchmarking of Partnership Activity
- 7.5. Benchmarking of Funding Activity
- 7.6. Benchmarking of Portfolio Strength
- 7.7. NAMPT Inhibitors: Company Competitiveness Analysis

8. COMPANY PROFILES

- 8.1. Antengene Therapeutics
 - 8.1.1. Company Overview
 - 8.1.2. Funding Information
 - 8.1.3. Product Portfolio
 - 8.1.4. Recent Developments and Future Outlook
- 8.2. Aqualung Therapeutics
 - 8.2.1. Company Overview
 - 8.2.2. Funding Information
 - 8.2.3. Product Portfolio
 - 8.2.4. Patent Portfolio
 - 8.2.5. Recent Developments and Future Outlook
- 8.3. Karyopharm Therapeutics
 - 8.3.1. Company Overview
 - 8.3.2. Financial Information
 - 8.3.3. Product Portfolio
 - 8.3.4. Patent Portfolio
 - 8.3.5. Recent Developments and Future Outlook
- 8.4. OncoTartis
 - 8.4.1. Company Overview
 - 8.4.2. Funding Information
 - 8.4.3. Product Portfolio
 - 8.4.4. Patent Portfolio
 - 8.4.5. Recent Developments and Future Outlook
- 8.5. Onxeo
 - 8.5.1. Company Overview
 - 8.5.2. Financial Information
 - 8.5.3. Product Portfolio
 - 8.5.4. Recent Developments and Future Outlook

9. PUBLICATION ANALYSIS

- 9.1. Methodology and Key Parameters
- 9.2. NAMPT Inhibitors: List of Publications
 - 9.2.1. Analysis by Year of Publication
 - 9.2.2. Analysis by Type of Publication
 - 9.2.3. Most Popular Journals: Analysis by Number of Publications
 - 9.2.4. Most Popular Publishers: Analysis by Number of Publications
 - 9.2.5. Analysis by Journal Impact Factor
 - 9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
 - 9.2.7. Analysis by Geography
 - 9.2.8. Emerging Focus Areas

10. GLOBAL EVENTS ANALYSIS

- 10.1. Methodology and Key Parameters
- 10.2. NAMPT Inhibitors: List of Global Events
 - 10.2.2. Cumulative Year-wise Trend
 - 10.2.3. Analysis by Type of Event
 - 10.2.4. Analysis by Event Platform
 - 10.2.5. Leading Players: Analysis by Number of Participants
 - 10.2.6. Leading Presenters: Analysis by Number of Participants
 - 10.2.7. Analysis by Geography

11. SOCIAL MEDIA ANALYSIS

- 11.1. Methodology and Key Parameters
 - 11.1.1. Cumulative Year-wise Activity
 - 11.1.2. Leading Users: Analysis by Number of Tweets
 - 11.1.3. Trending Words / Phrases on Twitter

12. DRUG FAILURE ANALYSIS

- 12.1. Methodology and Key Parameters
- 12.2. NAMPT Inhibitors: List of Failed Drug Candidates
 - 12.2.1. Analysis by Phase of Discontinuation
 - 12.2.2. Analysis by Trial Status
 - 12.2.3. Analysis by Target Indication
 - 12.2.4. Analysis by Route of Administration
 - 12.2.5. Analysis by Type of Sponsor
 - 12.2.6. Affiliated Stakeholders: Analysis by Number of Trials

- 12.2.7. Analysis by Reasons for Drug Failure
- 12.2.8. Key Terms in Study Results
- 12.2.9. Other Plausible Reasons for Drug Failure

13. FDA APPROVAL STRATEGIES

- 13.1. Methodology and Key Parameters
- 13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
- 13.3. Drug Specific Business Models followed by Company
- 13.4. Analysis of Drug Candidates by Business Model

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS

- 14.1. Key Assumptions and Parameters
- 14.2. Forecast Methodology
- 14.3. Global NAMPT Inhibitors Market, 2027-2040
- 14.4. List of Forecasted Drugs
 - 14.4.1. OT-82, OncoTartis
 - 14.4.1.1. Global Sales Forecast
 - 14.4.1.2. Regional Sales Forecast
 - 14.4.1.3. Net Present Value
 - 14.4.1.4. Value Creation Analysis
 - 14.4.2. ALT-100, Aqualung Therapeutics
 - 14.4.2.1. Global Sales Forecast
 - 14.4.2.2. Regional Sales Forecast
 - 14.4.2.3. Net Present Value
 - 14.4.2.4. Value Creation Analysis
 - 14.4.3. ATG-019, Antengene Therapeutics
 - 14.4.3.1. Global Sales Forecast
 - 14.4.3.2. Regional Sales Forecast
 - 14.4.3.3. Net Present Value
 - 14.4.3.4. Value Creation Analysis
 - 14.4.4. KPT-9274, Karyopharm Therapeutics
 - 14.4.4.1. Global Sales Forecast
 - 14.4.4.2. Regional Sales Forecast
 - 14.4.4.3. Net Present Value
 - 14.4.4.4. Value Creation Analysis
- 14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040

- 14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
- 14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040
- 14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
 - 14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
 - 14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040
- 14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
 - 14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
 - 14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
 - 14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
 - 14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040
- 14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
 - 14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
 - 14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040
- 14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
 - 14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
 - 14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040
- 14.10. NAMPT Inhibitors: Market Share of Key Players
- 14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: LIST OF FIGURES

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: NAMPT Inhibitor Market by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

Product link: <https://marketpublishers.com/r/N14B3DBF9152EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N14B3DBF9152EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970